Annexon, Inc. Share Price
ANNXAnnexon, Inc. Stock Performance
Open $6.98 | Prev. Close $7.00 | Circuit Range N/A |
Day Range $6.76 - $7.16 | Year Range $1.29 - $7.16 | Volume 56,660 |
Average Traded $6.94 |
Annexon, Inc. Share Price Chart
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
23-Jan-26 | $6.98 | $6.79 | +0.00% |
23-Jan-26 | $6.98 | $6.79 | -1.16% |
21-Jan-26 | $6.22 | $6.87 | +11.71% |
20-Jan-26 | $6.06 | $6.15 | +1.49% |
16-Jan-26 | $6.18 | $6.06 | -1.46% |
15-Jan-26 | $6.66 | $6.15 | -7.93% |
14-Jan-26 | $6.21 | $6.68 | +7.74% |